Data Insights

Prexigebersen by Bio-Path for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Prexigebersen in Relapsed Acute Myeloid Leukemia

Data Insights

Prexigebersen by Bio-Path for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Prexigebersen in Refractory Acute Myeloid Leukemia

Data Insights

Prexigebersen by Bio-Path for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....

Likelihood of Approval and Phase Transition Success Rate Model - Prexigebersen in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

BP-1002 by Bio-Path for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

BP-1002 is under clinical development by Bio-Path and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...

Data Insights

BP-1002 by Bio-Path for Cutaneous T-Cell Lymphoma: Likelihood of Approval

BP-1002 is under clinical development by Bio-Path and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase...

Data Insights

BP-1002 by Bio-Path for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

BP-1002 is under clinical development by Bio-Path and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...